Get notified when MIRM files again. Create a free account and we'll email you the moment its next filing is analyzed.

Get filing alerts
NASDAQ: MIRM Mirum Pharmaceuticals, Inc. 8-K

Mirum prices $690M convertible notes, uses $475M cash + 3.2M shares to refinance $237M of 2029 debt

Filed May 18, 2026 · Period ending May 12, 2026 · ~1 min read

Key Changes

  • high

    Issued $690M of 0% convertible notes due 2032 (conversion price $138.94/share, 30% premium to May 12 close). Net proceeds $671.6M after fees.

    Item 1.01 — Entry into a Material Definitive Agreement verify on EDGAR →
  • high

    Used $475M cash plus 3,220,529 shares to exchange $237.2M principal of existing 4% 2029 notes, eliminating near-term maturity and interest expense.

    Item 1.01 — Entry into a Material Definitive Agreement verify on EDGAR →
  • high

    Notes convert into up to 6.5M shares at initial rate of 9.3562 shares per $1,000 principal, subject to anti-dilution adjustments. Company may settle in cash, stock, or combination.

    Item 3.02 — Unregistered Sales of Equity Securities verify on EDGAR →

2 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.

Read 3 full reports/month free No card required. Takes 30 seconds.

Want to see a complete report first? Today's free report (GBCS 10-Q) is open in full — no account needed.

Partner

Trade MIRM commission-free

Open an account, get a free stock.

Sign up

Investing involves risk. Free stock terms apply.

Generated by AI · Jun 23, 2026 11:17 AM